These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 10431611)

  • 1. Role of lentiviral lytic polypeptide I (LLP-I) in the selective cytotoxicity of gamma-glutamylcysteine ethyl ester against human immunodeficiency virus type 1-producing cells.
    Kubota S; Zhang H; Kitahara S; Pomerantz RJ
    Antivir Chem Chemother; 1999 May; 10(3):121-7. PubMed ID: 10431611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel inhibitory effects of gamma-glutamylcysteine ethyl ester against human immunodeficiency virus type 1 production and propagation.
    Kubota S; Shetty S; Zhang H; Kitahara S; Pomerantz RJ
    Antimicrob Agents Chemother; 1998 May; 42(5):1200-6. PubMed ID: 9593150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion.
    Nagashima KA; Thompson DA; Rosenfield SI; Maddon PJ; Dragic T; Olson WC
    J Infect Dis; 2001 Apr; 183(7):1121-5. PubMed ID: 11237840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death.
    Barretina J; Blanco J; Armand-Ugón M; Gutiérrez A; Clotet B; Esté JA
    Antivir Ther; 2003 Apr; 8(2):155-61. PubMed ID: 12741628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viroporin potential of the lentivirus lytic peptide (LLP) domains of the HIV-1 gp41 protein.
    Costin JM; Rausch JM; Garry RF; Wimley WC
    Virol J; 2007 Nov; 4():123. PubMed ID: 18028545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular membrane-binding ability of the C-terminal cytoplasmic domain of human immunodeficiency virus type 1 envelope transmembrane protein gp41.
    Chen SS; Lee SF; Wang CT
    J Virol; 2001 Oct; 75(20):9925-38. PubMed ID: 11559825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency.
    Nomura W; Hashimoto C; Ohya A; Miyauchi K; Urano E; Tanaka T; Narumi T; Nakahara T; Komano JA; Yamamoto N; Tamamura H
    ChemMedChem; 2012 Feb; 7(2):205-8. PubMed ID: 22247043
    [No Abstract]   [Full Text] [Related]  

  • 8. A synthetic peptide corresponding to the carboxy terminus of human immunodeficiency virus type 1 transmembrane glycoprotein induces alterations in the ionic permeability of Xenopus laevis oocytes.
    Comardelle AM; Norris CH; Plymale DR; Gatti PJ; Choi B; Fermin CD; Haislip AM; Tencza SB; Mietzner TA; Montelaro RC; Garry RF
    AIDS Res Hum Retroviruses; 1997 Nov; 13(17):1525-32. PubMed ID: 9390752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effect of glutathione in HIV-1 lytic peptide 1-induced cell death in human neuronal cells.
    Sung JH; Shin SA; Park HK; Montelaro RC; Chong YH
    J Neurovirol; 2001 Oct; 7(5):454-65. PubMed ID: 11582518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
    Gustchina E; Hummer G; Bewley CA; Clore GM
    J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.
    Baldwin CE; Sanders RW; Deng Y; Jurriaans S; Lange JM; Lu M; Berkhout B
    J Virol; 2004 Nov; 78(22):12428-37. PubMed ID: 15507629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What's taking T-20 so long?
    Huff B
    GMHC Treat Issues; 2001 Apr; 15(4):1-3. PubMed ID: 11590938
    [No Abstract]   [Full Text] [Related]  

  • 13. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.
    Heredia A; Gilliam B; Latinovic O; Le N; Bamba D; Devico A; Melikyan GB; Gallo RC; Redfield RR
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2489-96. PubMed ID: 17485501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements.
    Ferrer M; Kapoor TM; Strassmaier T; Weissenhorn W; Skehel JJ; Oprian D; Schreiber SL; Wiley DC; Harrison SC
    Nat Struct Biol; 1999 Oct; 6(10):953-60. PubMed ID: 10504731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N36, a synthetic N-terminal heptad repeat domain of the HIV-1 envelope protein gp41, is an activator of human phagocytes.
    Le Y; Jiang S; Hu J; Gong W; Su S; Dunlop NM; Shen W; Li B; Ming Wang J
    Clin Immunol; 2000 Sep; 96(3):236-42. PubMed ID: 10964542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid.
    van Lelyveld SF; Nijhuis M; Baatz F; Wilting I; van den Bergh WM; Kurowski M; de Jong D; Hoepelman AI; Wensing AM
    Clin Infect Dis; 2010 Feb; 50(3):387-90. PubMed ID: 20047481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV genetic mutations causing resistance to the new drug T-20: recent findings.
    Bean P
    Am Clin Lab; 2002 Oct; 21(8):15-6. PubMed ID: 12440170
    [No Abstract]   [Full Text] [Related]  

  • 18. Impairment of excitatory amino acid transport in astroglial cells infected with the human immunodeficiency virus type 1.
    Kort JJ
    AIDS Res Hum Retroviruses; 1998 Oct; 14(15):1329-39. PubMed ID: 9788674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat.
    Izumi K; Nakamura S; Nakano H; Shimura K; Sakagami Y; Oishi S; Uchiyama S; Ohkubo T; Kobayashi Y; Fujii N; Matsuoka M; Kodama EN
    Antiviral Res; 2010 Aug; 87(2):179-86. PubMed ID: 20438763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential functional phenotypes of two primary HIV-1 strains resulting from homologous point mutations in the LLP domains of the envelope gp41 intracytoplasmic domain.
    Newman JT; Sturgeon TJ; Gupta P; Montelaro RC
    Virology; 2007 Oct; 367(1):102-16. PubMed ID: 17582453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.